Nuvation Bio Announces Promising Results from Phase 2 Studies of IBTROZI™ in ROS1-Positive Lung Cancer at 2025 Conference
Reuters
Sep 07
<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> Announces Promising Results from Phase 2 Studies of IBTROZI™ in ROS1-Positive Lung Cancer at 2025 Conference
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company, has announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. These findings are being highlighted in an oral presentation and poster session at the IASLC 2025 World Conference on Lung Cancer, taking place from September 6 to 9 in Barcelona, Spain. The results demonstrate sustained durability of responses with notable progression-free survival outcomes, especially in TKI-naïve patients, and show a favorable safety and tolerability profile for IBTROZI. The findings support the recent approval of IBTROZI in the U.S., adding a new treatment option for this form of lung cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250907734789) on September 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.